BenevolentAI S.A. (BAIVF)
| Market Cap | 10.78M |
| Revenue (ttm) | 6.15M |
| Net Income (ttm) | -64.97M |
| Shares Out | n/a |
| EPS (ttm) | -0.54 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 500 |
| Average Volume | 1,668 |
| Open | 0.2200 |
| Previous Close | 0.2200 |
| Day's Range | 0.2200 - 0.2200 |
| 52-Week Range | 0.5500 - 0.7200 |
| Beta | n/a |
| RSI | 25.87 |
| Earnings Date | Mar 14, 2025 |
About BenevolentAI
BenevolentAI S.A. operates as a clinical-stage artificial intelligence (AI) enabled drug discovery and development company. Its Benevolent platform integrates AI and science to uncover and develop drugs for complex diseases. The company’s development pipeline includes BEN-8744, an oral phosphodiesterase 10 (PDE10) inhibitor under phase 1 study for the treatment of Ulcerative Colitis; BEN-28010, an oral brain penetrant CHK1 inhibitor under preclinical study for the treatment of Glioblastoma Multiforme; BEN-34712, a preclinical candidate for the ... [Read more]
Financial Performance
In 2023, BenevolentAI's revenue was 7.33 million, a decrease of -30.58% compared to the previous year's 10.56 million. Losses were -63.32 million, -61.38% less than in 2022.
Financial numbers in GBP Financial StatementsNews
Proposed Delisting via Merger of BenevolentAI into Osaka Holdings S.à r.l. and Publication of Notice of Extraordinary General Meeting
LONDON--(BUSINESS WIRE)--Regulatory News: BenevolentAI, (“BenevolentAI” or “the Company”) (Euronext Amsterdam: BAI), a pioneer in AI-driven drug discovery, today announces: Subject to shareholder appr...
BenevolentAI Appoints Kenneth Mulvany as Executive Chairman
LONDON--(BUSINESS WIRE)--BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery and development, today announ...
BenevolentAI to Present on Explainable AI for Drug Discovery at BioTechX Europe 2024
LONDON--(BUSINESS WIRE)--BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that Dr James Malo...
BenevolentAI Notice of Interim Results
LONDON--(BUSINESS WIRE)--BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, will announce its interim re...
BenevolentAI: Appointment of Adviser
LONDON--(BUSINESS WIRE)--BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of...
BenevolentAI: Leadership Team Change
LONDON--(BUSINESS WIRE)--Regulatory News: BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced artificial intelligence (AI) to accelerate biopharma d...
BenevolentAI to participate in Goldman Sachs 45th Annual Global Healthcare Conference
LONDON--(BUSINESS WIRE)--BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that it will parti...